Dec 28
|
The 30 Happiest Cities in America in 2023
|
Dec 28
|
12 Best Stocks to Buy for an 18 Year Old
|
Dec 27
|
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
|
Dec 23
|
Should You Be Adding Gilead Sciences (NASDAQ:GILD) To Your Watchlist Today?
|
Dec 21
|
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
|
Dec 21
|
Gilead Sciences to Present at Upcoming Investor Conference
|
Dec 21
|
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
|
Dec 21
|
Gilead Stock Could Finally Have a Breakout Year. Here’s Why.
|
Dec 20
|
Gilead Sciences (GILD) Stock Moves -1.13%: What You Should Know
|
Dec 20
|
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
|
Dec 20
|
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
|
Dec 19
|
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
|
Dec 7
|
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
|
Dec 7
|
Gilead Sciences: The Bull Case Is More Powerful Than You Think
|
Dec 7
|
Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
|
Dec 6
|
Great week for Gilead Sciences, Inc. (NASDAQ:GILD) institutional investors after losing 6.8% over the previous year
|
Dec 2
|
Is Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 26% Impressive?
|
Dec 1
|
Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt
|
Nov 30
|
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
|
Nov 30
|
2 Biotech Stocks You Can Buy and Hold for the Next Decade
|